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     One of the leading causes of death in the world are cardiovascular diseases, among which coronary artery 
disease (CAD) is the most common one. It occurs as a result of narrowing of the arteries which supply blood 
to the heart due to a theroma plaque formation. This kind of heart disease can be considered as a 
multifactorial one as genetic and environmental factors are involved in its incidence. The already conducted 
studies have investigated the relationship between some of polymorphisms in different loci and CAD with 
the aim of on-time diagnosis of this disease, which may lead to its prevention and appropriate treatment. The 
aim of this study was to examine the association of tRNA Thr 15927 G → A mutation with the risk of CAD 
incidence to offer programs for early diagnosis and treatment of this disease in Iran. Fifty patients with CAD 
were included in the patient group, and fifty healthy participants were selected for the control group. 5mL of 
peripheral blood samples drawn from subjects in patient and control groups were collected in the tubes 
containing Ethylenediaminetetraacetic acid (EDTA). After DNA extraction from blood with the employment 
of DNA extraction kit, its quality and quantity were measured using electrophoresis and NanoDrop devices, 
respectively. Then, the isolated DNA with the implementation of  amplification-refractory mutation 
system (ARMS)  and restriction fragment length polymorphism (RFLP) techniques was examined to 
determine and evaluate the target polymorphism in the intended locus. Sequencing method was also used to 
confirm the findings. To this end, 4 samples were randomly selected and sequenced.In the control group, 6 
screened patients had the mutation while the others did not. Similar result was observed in the patient group. 
The findings of the present study reveal that there was not any significant relationship between tRNAThr 
15927G → A mutation and risk of CAD incidence. 
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INTRODUCTION 
     Heart disease can be considered as the leading 
cause of sudden death all over the world. Its most 
prevalent type is coronary artery stenosis or CAD. 
According to the statistics presented at the 11
th
 
Recent Findings of Cardiology Congress 
administered in June 2009, 38 to 40% of deaths 
are caused by cardiovascular diseases in Iran. 
Furthermore, 198 Iranian individuals die from 
heart attack per day [1-5]. CAD is a multifactorial 
disease, in which the significant role of factors 
such as environmental conditions, life style, and 
nuclear genetics has been acknowledged [6, 7]. 
As heart requires ionic balance in its muscle to 
regularly pump and circulate blood in the body, 
and since the proper functioning of mitochondria 
is regarded as the balancing factor, the significant 
role of mitochondrial genetics in CAD becomes 
apparent [8, 9]. High blood pressure is specified 
as a major risk for the incidence of CAD diseases. 
A good number of studies have been conducted 
with respect to the congenital blood pressure 
revealing the role of mitochondria in disease 
transmission from mother to child. It is well 
acknowledged that mitochondrial genome is 
inherited only from mother [10-14]. Each 
mitochondria contains multiple copies of double-
stranded and circular mitochondrial DNA known 
as mtDNA. Human mtDNA encodes 13critical 
subunits of the inner membrane, which are 
 




responsible for oxidative phosphorylation. For the 
translation of RNA in mitochondrial protein 
synthesis system, 22mt-tRNA produced by 
mtDNA are required. The unique structure of mt-
tRNAs distinguishes them from cytoplasmic 
tRNAs.  Coding Mt-tRNA genes are highly 
mutatable and are regarded as the main factors 
causing malfunction of the mitochondria [15-17]. 
Knowing that one or more mutations accompany 
a disease paves the path of preventing the risk of 
the mentioned disease incidence [18, 19]. 
Officially, 32 mutations have been reported in 
genes relevant to mt-tRNA, of which only two 
have been specified to be pertinent to CAD [20]. 
In another analysis conducted on patients with 
congenital heart disease, 65 mitochondrial 
mutations were found while 13 of them were 
quite new ones [21]. However, by far, few 
statistical studies have been conducted to test the 
association of the mentioned mutations with heart 
diseases. Zidong Jia et al. (2013) can be 
considered as the first group of researchers 
examining the relationship between the point 
mutation known as tRNA-Thr 15927 and CAD 
disease. They focused their study on four 
generations of a Chinese family, in which 13 out 
of 32 adults suffered from congenital CAD. It was 
found that a mutation from G to A (G → A) took 
place at 15927 region of the amino acid threonine 
tRNA gene. As a result of the mentioned 
mutation, reduction in the efficiency occurs in the 
amino acetylated tRNA-Thr, which ultimately 
reduces 53% of mitochondrial translation in the 
mutant cells [22]. In this regard, the aim of the 
present study was to investigate the association of 
RNA-Thr15927 single nucleotide mutation with 
CAD disease in Iran’s statistical population. 
MATERIALS AND METHODS 
     To investigate the association of tRNA Thr 
15927G → A mutation with CAD disease,  
individuals whose disease were proved employing 
WHO indices were chosen. Fifty patients with 
CAD were included in the patient group, and fifty 
healthy participants were selected for the control 
group.  For this study, all individuals filled a 
written informed consent form. Both males and 
females with an average age of 58-59 years and 
all above 40 years of age took part in the study. 
5ml of blood was drawn from each person and 
kept in tubes containing EDTA at -20° c for the 
intended tests to be performed on them. First, a 
standard column kit was used to extract DNA 
from the samples. Then, in order to verify the 
quality of the extracted DNA, its purity was 
approved, using gel electrophoresis and 
NanoDrop device. The obtained OD spectrum 
(using NanoDrop device) at a wave length of 
260nm to280nm was between 1/77 and 1/90. For 
a pure sample of DNA, the ratio should be about 
1/8. In the next step, a primer was designed with 
the implementation of Primer3Plus and 
OligoAnalizer softwares to perform PCR-RFLP 
and PCR-ARMS techniques. Regarding PCR-
ARMS, two forward primers, i.e. 
TACGGYTACCTTGTTACGAC and 
TACACCAGTCTTGTAAACCA and one reverse 
primer, i.e. TGGCAGTAATGTACGAAATAC 
were employed. PCR product along with the 
mentioned primers made a fragment with 202 
base pair length. To perform PCR-RFLP, forward 
primer called ATCATTGGACAAGTAGCATC 
and reverse primer known as 
TGGCAGTAATGTACGAAATAC were 
employed. As a result of these two primers’ 
patterning, the PCR product had the length of 319 
base pair. In the application of PCR-RFLP 
technique, after implementation of PCR, 
enzymatic digestion of the amplified fragment 
was done, then it was transferred onto the gel for 
verification of the band pattern. To address this 
objective, HpaII enzyme with the CCGG 
recognition sequence was used in this study. If the 
under investigation individual has nucleotide A in 
his 15927 mtDNA, only a 319 base pair fragment 
will be present after enzyme digestion by HpaII 
enzyme as sequencing of a CCGG enzyme has 
not taken place and no incision has been 
performed. However, if the individual in his 
15927 mtDNA has nucleotide G, two 135 and 184 
base pair fragments will be present after enzyme 
digestion by HpaII enzyme. In the last step and 
for the final confirmation of the presence or 
absence of tRNA Thr 15927G→A mutation, the 
ARMS technique was implemented on samples. 
In the application of this technique, if nucleotide 
G is in the region of SNP, 
TACACCAGTCTTGTAAACCG forward primer 
will yield product in PCR reaction, and if 
nucleotide G is in the region of SNP, 
 




TACACCAGTCTTGTAAACCA forward primer 
will yield product in PCR reaction. At the end, for 
ultimate confirmation of the results obtained 
through the implementation of the two methods, 4 
samples were quite randomly selected and sent for 
sequencing the intended region. The accuracy of 
the results was ensured after examining the 
received results and checking their compliance 
with ARMS and RFLP results. 
RESULTS 
     Considering the results obtained by performing 
agarose gel electrophoresis of PCR product, it 
was found that out of 100 involved cases,12 had 
polymorphism A, 6 of which belonged to the 
patient group and the other 6 were members of 
control group. 
 
Figure 1. Electrophoresis of  PCR product in ARMS technique is 
negative with no band, which indicates the authenticity of the 
study and the absence of contamination in the product 1G and 2G  
present samples having forward primer, which amplify the strand 
containing G allele. 1A and 2A are samples having forward 
primer, amplifying the strand containing allele A. Reverse primer 
is similar for both samples. In this figure, both of the investigated 
samples have allele G. 
Figure2. Electrophoresis of PCR product in RFLP technique. 
is negative with no band, which indicates the authenticity of 
the study and the absence of contamination in the product.1 
to16 contain PCR product of 16 involved cases, and single 
band was observed in all cases, which reveals the accuracy of 
the study and appropriate performance of the designed pair 
primers. 
 
Figure 3. Electrophoresis of enzyme-digested product in 
RFLP technique. These are the same 16 cases, which were 
mentioned in the previous figure. After enzyme digestion by 
HpaII enzyme, only sample 3 had allele A, which was not 
identified and cut by the enzyme. The remaining 15 samples 
all had allele G, which were identified and cut by the HpaII 
enzyme and were shown as two bands in the figure. 
 
 
Figure 4. Sequencing Results: The presented nucleotide is 
target polymorphisms; here, it is nucleotide G. 
 
 





     Deposition of fatty substances on the inner 
lining of the coronary arteries is the major cause 
of heart embolism; in fact, CAD occurs due to the 
accumulation of atherosclerotic plaques in the 
coronary arteries. As a result of the accumulation 
of atherosclerotic plaques in coronary arteries, 
blood and eventually oxygen supply to the heart 
decrease. Severe reduction in the blood flow to 
the heart, due to CAD disease, may lead to the 
loss of heart cell activities, and if this trend 
continues, heart cells die.  This phenomenon is 
known as a myocardial infarction or heart attack. 
CAD and MI can be considered as the main 
causes of death all over the world. According to 
the World Health Organization, by 2030 more 
than 23 million people will die as a result of heart 
diseases. In this regard, many countries such as 
America have allocated a billion-dollar budget for 
conducting prevention and treatment studies with 
respect to heart diseases. So far, a good number of 
the studies have been conducted addressing 
association of genetics with susceptibility to CAD 
with a focus on the nuclear genome. Ozaki et 
al.(2002) [23] using 92,788 gene-based SNP 
markers have conducted the first genome wide 
genomic association study in the world with 
regard to this disease. Their target population was 
Japanese patients. The obtained results revealed 
that two SNPs in lenfotoksin A (LTA) in 6p21 
locus were significantly associated with the 
increased risk of MI in the Japanese population 
[23]. In another study, Helgadottir et al. (2007) 
[24] focused on 4587patient cases (positive 
angiography) and 12767 control cases; they 
determined the genotype of 305,953 cases. All the 
studied cases were of European ancestry. For the 
first time, the obtained results demonstrated a 
strong association between CAD and variants in 
9p21 locus. They revealed that allele G in 
rs10757278 polymorphism had strong 
relationship with MI. In another research, 
McPherson et al.(2007) [25] identified two SNPs 
(rs10757274 and rs2383206) on chromosomal  
 
region 9p21, which were associated with 15 to 
20% increased risk of CAD in 50% of 
heterozygous cases, and 40%  increased risk in 
25% of homozygous cases. Moreover, in the 
study carried out by the Consortium WTCCC 
involving 1926 patient cases and 2938 control 
cases, significant association was observed 
between SNPs of chromosome 9p21 and CAD 
(Burton et al., 2007) [26]. In another study 
involving 875 patients and 1644 healthy German 
participants using Affymetrix kit, the strongest 
association was noticed between CAD and 
rs1333049 locus. [27]. A number of studies have 
also been conducted addressing haplotype 
determination and their association with CAD 
disease. The first study with respect to haplotypes 
was carried out by WTCCC group examining MI 
on the German population, in which SLC22A3-
LPAL2-LPA gene cluster on chromosome 6q26-
27 was identified as the potential locus for CAD 
(OR = 1.8 [28 ]. Another study was conducted in 
China to investigate whether mitochondrial DNA 
defects were associated with the risk of CHD. A 
systematic and continuous screening of 
mitochondrial mutations was conducted on a large 
group of Chinese patients with CHD. In their 
mitochondrial DNA mutation analysis, a   G→A 
15927 tRNAThr mutation was recognized (88). 
This G→ A 15927 tRNA Thr mutation was 
observed in the anticodon stem of the tRNAThr 
protected region [29 ,30]. 
CONCLUSION  
     ARMS and RFLP techniques were employed 
in this study and sequencing was used to confirm 
the results. As no significant difference was 
observed between the two studied groups with 
respect to the prevalence of alleles A and G, and  
Pval< 0/5 was obtained using SPSS(Ver. 15), the 
present study reported no association between the 
mentioned polymorphism and coronary artery 
disease(CAD). 
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